auto-fix: strip 2 broken wiki links

Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.

domains/entertainment/creator-owned-streaming-infrastructure-has-reached-commercial-scale-with-430M-annual-creator-revenue-across-13M-subscribers.md

@@ -68,6 +68,16 @@ Dropout specifically contributes $30M+ ARR to the indie streaming category total
 
 Dropout crossed 1 million subscribers in October 2025 with 31% year-over-year growth, representing a major indie streaming platform reaching seven-figure subscriber scale. This adds to the evidence that creator-owned streaming is commercially viable at scale.
 
+
+### Auto-enrichment (near-duplicate conversion, similarity=1.00)
+*Source: PR #1435 — "creator owned streaming infrastructure has reached commercial scale with 430m annual creator revenue across 13m subscribers"*
+*Auto-converted by substantive fixer. Review: revert if this evidence doesn't belong here.*
+
+### Additional Evidence (confirm)
+*Source: [[2024-00-00-markrmason-dropout-streaming-model-community-economics]] | Added: 2026-03-19*
+
+Dropout's $30M+ ARR as a single indie streaming platform provides a concrete data point for the aggregate creator-owned streaming revenue. The platform demonstrates that niche content (TTRPG actual play, game shows) can sustain profitable streaming operations at scale without mass-market positioning.
+
 ---
 
 Relevant Notes:

domains/entertainment/worldbuilding-as-narrative-infrastructure-creates-communal-meaning-through-transmedia-coordination-of-audience-experience.md

@@ -72,6 +72,16 @@ Martin Cooper, inventor of the first handheld mobile phone, directly contradicts
 
 SCP Foundation demonstrates that worldbuilding-as-infrastructure can operate at massive scale (9,800+ objects, 16 language branches, 18 years) through protocol-based coordination without central creative authority. The 'no official canon' model — 'a conglomerate of intersecting canons, each with its own internal coherence' — enables infinite expansion without continuity errors. This is worldbuilding as emergent coordination infrastructure, not designed master narrative.
 
+
+### Auto-enrichment (near-duplicate conversion, similarity=1.00)
+*Source: PR #1434 — "worldbuilding as narrative infrastructure creates communal meaning through transmedia coordination of audience experience"*
+*Auto-converted by substantive fixer. Review: revert if this evidence doesn't belong here.*
+
+### Additional Evidence (challenge)
+*Source: [[2015-00-00-cooper-star-trek-communicator-cell-phone-myth-disconfirmation]] | Added: 2026-03-19*
+
+Martin Cooper, inventor of the first handheld cellular phone, directly contradicts the Star Trek communicator origin story. Motorola began developing handheld cellular technology in the late 1950s, before Star Trek premiered in 1966. Cooper stated he had been 'working at Motorola for years before Star Trek came out' and 'they had been thinking about hand held cell phones for many years before Star Trek came out.' Cooper later clarified that when he appeared in 'How William Shatner Changed the World,' he 'was just so overwhelmed by the movie' and conceded to something 'he did not actually believe to be true.' The technology predated the fiction, making causal influence impossible. The only confirmed influence was design aesthetics: the Motorola StarTAC flip phone (1996) mirrored the communicator's flip-open mechanism decades after the core technology existed.
+
 ---
 
 Relevant Notes:

domains/entertainment/youtube-first-distribution-for-major-studio-coproductions-signals-platform-primacy-over-traditional-broadcast-windowing.md

@@ -53,10 +53,16 @@ Claynosaurz 39-episode animated series launching YouTube-first before selling to
 
 
 ### Additional Evidence (extend)
-*Source: [[2025-05-16-lil-pudgys-youtube-launch-thesoul-reception-data]] | Added: 2026-03-19*
+*Source: 2025-05-16-lil-pudgys-youtube-launch-thesoul-reception-data | Added: 2026-03-19*
 
 Lil Pudgys launched YouTube-first with 13,000 subscribers at premiere (May 2025), relying on TheSoul Publishing's 2B+ social follower network for cross-platform promotion. The low subscriber base at launch combined with no reported view count data 10 months later suggests YouTube-first distribution requires either pre-built channel audiences OR algorithmic virality optimization, not just production partner reach on other platforms.
 
+
+### Additional Evidence (confirm)
+*Source: [[2025-10-01-variety-claynosaurz-creator-led-transmedia]] | Added: 2026-03-19*
+
+Claynosaurz 39-episode animated series launching on YouTube first before selling to TV/streaming, co-produced with Method Animation (Mediawan). Nic Cabana frames this as 'already here' not speculative, with community's 1B social views creating guaranteed algorithmic traction that studios pay millions to achieve through marketing.
+
 ---
 
 Relevant Notes:

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -115,10 +115,16 @@ International generic competition beginning January 2026 (Canada patent expiry,
 
 
 ### Additional Evidence (challenge)
-*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-19*
+*Source: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach | Added: 2026-03-19*
 
 If GLP-1 + exercise combination produces durable weight maintenance (3.5 kg regain vs 8.7 kg for medication alone), and if behavioral change persists after medication discontinuation, then the chronic use model may not be necessary for long-term value capture. This challenges the inflationary cost projection if the optimal intervention is time-limited medication + permanent behavioral change rather than lifetime pharmacotherapy.
 
+
+### Additional Evidence (challenge)
+*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-19*
+
+Aon's 192,000+ patient analysis shows the inflationary impact is front-loaded and time-limited: costs rise 23% vs 10% in year 1, but after 12 months medical costs grow just 2% vs 6% for non-users. At 30 months for diabetes patients, medical cost growth is 6-9 percentage points lower. This suggests the 'inflationary through 2035' claim may be true only for short-term payers who never capture the year-2+ savings, while long-term risk-bearers see net cost reduction. The inflationary impact depends on payment model structure, not just the chronic use model itself.
+
 ---
 
 Relevant Notes:

domains/health/federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings.md

@@ -57,6 +57,16 @@ IMPaCT's $2.47 Medicaid ROI within the same fiscal year demonstrates that at lea
 
 VBID termination was driven by $2.3B excess costs in CY2021-2022, measured within a short window that could not capture long-term savings from food-as-medicine interventions. CMS cited 'unprecedented' excess costs as justification, demonstrating how short-term cost accounting drives policy decisions even for preventive interventions with strong theoretical long-term ROI.
 
+
+### Auto-enrichment (near-duplicate conversion, similarity=1.00)
+*Source: PR #1436 — "federal budget scoring methodology systematically undervalues preventive interventions because 10 year window excludes long term savings"*
+*Auto-converted by substantive fixer. Review: revert if this evidence doesn't belong here.*
+
+### Additional Evidence (confirm)
+*Source: [[2024-10-31-cms-vbid-model-termination-food-medicine]] | Added: 2026-03-19*
+
+VBID termination cited $2.3-2.2 billion annual excess costs as justification, but this accounting captures only immediate expenditures for food/nutrition benefits, not the long-term savings from preventing chronic disease in food-insecure populations. The 10-year scoring window excludes the 15-30 year horizon where food-as-medicine ROI materializes through reduced diabetes, cardiovascular disease, and other chronic conditions. A program with positive lifetime ROI was terminated for 'excess costs' that ignore downstream savings.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md

@@ -66,6 +66,12 @@ Medicare modeling quantifies the compound value: 38,950 CV events avoided, 6,180
 
 Aon's 192K patient study found adherent GLP-1 users (80%+) had 47% fewer MACE hospitalizations for women and 26% for men, with the sex differential suggesting larger cardiovascular benefits for women than previously documented.
 
+
+### Additional Evidence (extend)
+*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-19*
+
+Aon's 192,000+ patient analysis adds cancer risk reduction to the multi-organ benefit profile: female GLP-1 users showed ~50% lower ovarian cancer incidence and 14% lower breast cancer incidence. Also associated with lower rates of osteoporosis, rheumatoid arthritis, and fewer hospitalizations for alcohol/drug abuse and bariatric surgery. The sex-differential in MACE reduction (47% for women vs 26% for men) suggests benefits may be larger for women, which has implications for risk adjustment in Medicare Advantage.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md

@@ -97,10 +97,16 @@ GLP-1 behavioral adherence failures demonstrate that even breakthrough pharmacol
 
 
 ### Additional Evidence (extend)
-*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-19*
+*Source: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach | Added: 2026-03-19*
 
 Weight regain data shows GLP-1 alone (8.7 kg regain) performs no better than placebo (7.6 kg) after discontinuation, while combination with exercise reduces regain to 3.5 kg. This suggests the low persistence rates may be economically rational from a patient perspective if medication alone provides no durable benefit—patients who discontinue without establishing exercise habits return to baseline regardless of medication duration.
 
+
+### Additional Evidence (extend)
+*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-19*
+
+Aon data shows benefits scale dramatically with adherence: for diabetes patients, medical cost growth is 6 percentage points lower at 30 months overall, but 9 points lower with 80%+ adherence. For weight loss patients, cost growth is 3 points lower at 18 months overall, but 7 points lower with consistent use. Adherent users (80%+) show 47% fewer MACE hospitalizations for women and 26% for men. This confirms that adherence is the binding variable—the 80%+ adherent cohort shows the strongest effects across all outcomes, making low persistence rates even more economically damaging.
+
 ---
 
 Relevant Notes:

entities/ai-alignment/uk-aisi.md

@@ -41,6 +41,14 @@ The first government-established AI safety evaluation body, created after the Bl
 - **2025-07-00** — Conducted international joint testing exercise on agentic systems
 - **2025-05-00** — Released HiBayES statistical modeling framework
 - **2024-04-00** — Released open-source Inspect evaluation framework
+- **2026-03-16** — Conducted cyber capability testing on 7 LLMs on custom-built cyber ranges
+- **2026-03-00** — Renamed from 'AI Safety Institute' to 'AI Security Institute'
+- **2026-02-25** — Released Inspect Scout transcript analysis tool
+- **2026-02-17** — Conducted universal jailbreak assessment against best-defended systems
+- **2025-10-22** — Released ControlArena library for AI control experiments
+- **2025-07-00** — Conducted international joint testing exercise on agentic systems
+- **2025-05-00** — Released HiBayES statistical modeling framework
+- **2024-04-00** — Released open-source Inspect evaluation framework
 ## Alignment Significance
 The UK AISI is the strongest evidence that institutional infrastructure CAN be created from international coordination — but also the strongest evidence that institutional infrastructure without enforcement authority has limited impact. Labs grant access voluntarily. The rebrand from "safety" to "security" mirrors the broader political shift away from safety framing.
 

entities/entertainment/dropout.md

@@ -27,6 +27,7 @@ Creator-owned streaming platform focused on comedy content. Reached 1M+ subscrib
 - **2025-10-01** — Crossed 1 million subscribers (31% YoY growth). Launched $129.99/year superfan tier in response to fan requests for higher-priced support option. Dimension 20 MSG live show sold out (January 2025). Brennan Lee Mulligan signed 3-year deal while simultaneously participating in Critical Role Campaign 4.
 - **2025-10-01** — Crossed 1 million subscribers with 31% YoY growth; launched $129.99/year superfan tier in response to fan requests to support platform
 - **2025-10-01** — Crossed 1 million subscribers (31% YoY growth); launched $129.99/year superfan tier originated by fan request
+- **2025-10-01** — Crossed 1 million subscribers (31% YoY growth). Launched superfan tier at $129.99/year in response to fan requests for higher-priced support option.
 ## Relationship to KB
 
 - [[creator-owned-streaming-infrastructure-has-reached-commercial-scale-with-430M-annual-creator-revenue-across-13M-subscribers]]

entities/internet-finance/p2p-me.md

@@ -54,4 +54,5 @@ Treasury controlled by token holders through futarchy-based governance. Team can
 - **March 15, 2026** — Pine Analytics publishes pre-ICO analysis identifying 182x gross profit multiple concern
 - **March 26, 2026** — ICO scheduled on MetaDAO
 
-- **2026-03-26** — [[p2p-me-metadao-ico]] Active: ICO scheduled, targeting $6M raise at $15.5M FDV with Pine Analytics identifying 182x gross profit multiple concerns
+- **2026-03-26** — [[p2p-me-metadao-ico]] Active: ICO scheduled, targeting $6M raise at $15.5M FDV with Pine Analytics identifying 182x gross profit multiple concerns
+- **2026-03-26** — [[p2p-me-ico-march-2026]] Active: $6M ICO at $15.5M FDV scheduled on MetaDAO

inbox/archive/entertainment/2025-10-01-variety-claynosaurz-creator-led-transmedia.md

@@ -7,9 +7,13 @@ date: 2025-10-01
 domain: entertainment
 secondary_domains: []
 format: article
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [claynosaurz, creator-led, transmedia, youtube-distribution, community-first]
+processed_by: clay
+processed_date: 2026-03-19
+enrichments_applied: ["youtube-first-distribution-for-major-studio-coproductions-signals-platform-primacy-over-traditional-broadcast-windowing.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -45,3 +49,12 @@ Variety article on Nic Cabana's VIEW Conference presentation on Claynosaurz's cr
 PRIMARY CONNECTION: progressive validation through community building reduces development risk by proving audience demand before production investment
 WHY ARCHIVED: Evidences the YouTube-first distribution model as operational (not theoretical) — community as marketing engine for platform-based distribution
 EXTRACTION HINT: The key insight isn't the YouTube distribution per se but the COMMUNITY→ALGORITHM dynamic: pre-existing community creates launch traction that normally costs millions in marketing. This is a specific mechanism claim.
+
+
+## Key Facts
+- Claynosaurz has 39 x 7-minute animated episodes in production
+- Method Animation (Mediawan) is co-production partner
+- Gameloft mobile game in co-development
+- Claynosaurz community has generated nearly 1B social views
+- Nic Cabana presented at VIEW Conference 2025
+- Internal incubator for creative teams planned

inbox/archive/health/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md

@@ -7,13 +7,17 @@ date: 2026-01-13
 domain: health
 secondary_domains: [internet-finance]
 format: report
-status: unprocessed
+status: enrichment
 priority: high
 tags: [glp-1, employer-costs, cancer-risk, cardiovascular, cost-offset, real-world-evidence]
 processed_by: vida
 processed_date: 2026-03-18
 enrichments_applied: ["glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"]
 extraction_model: "anthropic/claude-sonnet-4.5"
+processed_by: vida
+processed_date: 2026-03-19
+enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -64,3 +68,16 @@ flagged_for_rio: ["GLP-1 cost dynamics have direct implications for health inves
 - Female GLP-1 users: ~50% lower ovarian cancer incidence, 14% lower breast cancer incidence
 - Adherent users (80%+): 47% fewer MACE hospitalizations for women, 26% for men
 - Study released January 13, 2026
+
+
+## Key Facts
+- Aon analyzed 192,000+ GLP-1 users in U.S. commercial health claims data
+- Study released January 13, 2026
+- First 12 months on Wegovy/Zepbound: medical costs rise 23% vs 10% for non-users
+- After 12 months: medical costs grow 2% vs 6% for non-users
+- Diabetes indication at 30 months: medical cost growth 6 percentage points lower; 9 points lower with 80%+ adherence
+- Weight loss indication at 18 months: cost growth 3 points lower; 7 points lower with consistent use
+- Female GLP-1 users: ~50% lower ovarian cancer incidence
+- Female GLP-1 users: 14% lower breast cancer incidence
+- Adherent users (80%+): 47% fewer MACE hospitalizations for women, 26% for men
+- Also associated with lower rates of osteoporosis, rheumatoid arthritis, alcohol/drug abuse hospitalizations

inbox/queue/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json

@@ -1,13 +1,13 @@
 {
   "rejected_claims": [
     {
-      "filename": "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md",
+      "filename": "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-medical-savings-lag-drug-costs-by-12-18-months.md",
       "issues": [
         "missing_attribution_extractor"
       ]
     },
     {
-      "filename": "glp-1-female-users-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction.md",
+      "filename": "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-in-women-suggesting-multi-system-benefits-beyond-metabolic-endpoints.md",
       "issues": [
         "missing_attribution_extractor"
       ]
@@ -19,14 +19,14 @@
     "fixed": 2,
     "rejected": 2,
     "fixes_applied": [
-      "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:set_created:2026-03-18",
-      "glp-1-female-users-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction.md:set_created:2026-03-18"
+      "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-medical-savings-lag-drug-costs-by-12-18-months.md:set_created:2026-03-19",
+      "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-in-women-suggesting-multi-system-benefits-beyond-metabolic-endpoints.md:set_created:2026-03-19"
     ],
     "rejections": [
-      "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:missing_attribution_extractor",
-      "glp-1-female-users-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction.md:missing_attribution_extractor"
+      "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-medical-savings-lag-drug-costs-by-12-18-months.md:missing_attribution_extractor",
+      "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-in-women-suggesting-multi-system-benefits-beyond-metabolic-endpoints.md:missing_attribution_extractor"
     ]
   },
   "model": "anthropic/claude-sonnet-4.5",
-  "date": "2026-03-18"
+  "date": "2026-03-19"
 }

inbox/queue/2025-03-28-futardio-proposal-should-sanctum-build-a-sanctum-mobile-app-wonder.md

@@ -1,52 +0,0 @@
----
-type: source
-source_id: 2025-03-28-futardio-proposal-should-sanctum-build-a-sanctum-mobile-app-wonder
-title: "Futardio Proposal: Should Sanctum Build a Sanctum Mobile App (Wonder)?"
-url: https://futarchy.substack.com/p/proposal-should-sanctum-build-a-sanctum
-author: Futarchy.io / Sanctum team
-date_published: 2025-03-28
-date_accessed: 2025-03-28
-processed_date: 2025-03-28
-processed_by: knowledge-base-maintainer
-claims_extracted:
-  - consumer-crypto-adoption-requires-apps-optimized-for-earning-and-belonging
-  - sanctum-wonder-mobile-app-proposal-failed-futarchy-vote-march-2025
-enrichments_applied:
-  - futarchy-governed-DAOs-converge-on-traditional-corporate-governance-scaffolding-over-time
-  - optimal-governance-requires-mixing-mechanisms-for-different-decision-types
-tags: [futarchy, metadao, sanctum, governance, consumer-crypto]
----
-
-# Futardio Proposal: Should Sanctum Build a Sanctum Mobile App (Wonder)?
-
-## Summary
-
-Proposal submitted to MetaDAO's futarchy governance mechanism asking whether Sanctum should build "Wonder" - a consumer mobile application combining social features with yield generation. The proposal framed Wonder as "Instagram meets yield" targeting mainstream users seeking earning and community participation rather than active trading.
-
-## Key Details
-
-- **Proposer**: Sanctum team
-- **Governance mechanism**: MetaDAO futarchy (CLOUD token markets)
-- **Proposal date**: March 28, 2025
-- **Outcome**: Failed
-- **Strategic context**: Pivot from infrastructure to consumer products
-- **Company context**: Sanctum raised at $3B valuation (January 2025)
-
-## Core Thesis
-
-Sanctum's product vision: "We believe the next wave of crypto adoption will come from apps that make earning and belonging delightful, not from better trading interfaces."
-
-## Product Concept
-
-**Wonder mobile app**:
-- Social features + passive yield generation
-- Target: mainstream users, not crypto-native traders
-- Success metrics: DAU and retention vs. trading volume
-- Positioning: consumer fintech meets social network
-
-## Archival Notes
-
-- Source processed: 2025-03-28
-- Claims extracted: 2 (consumer crypto thesis, futarchy governance case study)
-- Enrichments: Added context to existing futarchy mechanism claims
-- Timeline note: All dates are 2025 (source created and processed same year)

inbox/queue/2026-02-26-futardio-launch-delay-test.md

@@ -1,31 +0,0 @@
----
-type: claim
-title: "Futardio Launch Delay Test Data"
-description: "Test data for null-result archive extraction - no material claims"
-domains:
-  - crypto/solana/tokens
-date_claimed: 2026-02-26
-date_occurred: 2026-02-26
-confidence: null
-status: archive
-source:
-  - type: test_data
-    url: null
-extraction_notes: "This is test data for validating null-result archive handling. No material claims to extract."
----
-
-# Futardio Launch Delay Test Data
-
-This is non-material test data used to validate the extraction pipeline's handling of null-result archive content.
-
-## Launch Details
-
-- **Token**: Futardio
-- **Mint Address**: `92b2kFRVjtY4txYqvCVMjv4xuDgkL5DJ6mRkcbbcmeta`
-- **Original Launch Date**: February 26, 2026
-- **Status**: Delayed (test scenario)
-- **Reason**: Simulated technical issues (test data)
-
-## Extraction Notes
-
-This file serves as test data for the knowledge base extraction system. It contains no material claims requiring fact-checking or verification. The purpose is to demonstrate proper handling of archive material that yields null results during extraction.

inbox/queue/2026-02-26-futardio-launch-fitbyte.md

@@ -1,39 +0,0 @@
----
-type: source
-source_id: 2026-02-26-futardio-launch-fitbyte
-title: FutarchyDAO Launch - FitByte
-url: https://futarchy.metadao.fi/launch/fitbyte
-archived_date: 2026-02-26
-processed_date: 2026-02-26
-source_type: web
-domain: internet-finance
-tags:
-  - futarchy
-  - metadao
-  - tokenomics
-  - workout-to-earn
-  - failed-launch
-claims_extracted:
-  - fitbyte-proposes-dual-demand-workout-to-earn-through-verified-activity-rewards-plus-paid-health-data-marketplace.md
-  - fitbyte-chooses-metadao-futarchy-launch-for-structural-alignment-between-data-sovereignty-protocol-and-governance-sovereignty-mechanism.md
----
-
-# Summary
-
-FitByte attempted to launch a workout-to-earn token via MetaDAO's futarchy mechanism on 2026-02-26. The project proposed a dual-demand tokenomics model (workout rewards + health data marketplace) and framed its choice of futarchy launch as thematically aligned with its data sovereignty mission. The launch failed dramatically, raising only $23 against a $500k target. All funds were refunded.
-
-# Key Claims Extracted
-
-1. **Dual-demand tokenomics**: FitByte proposed combining workout-to-earn token emission with a paid health data marketplace to create sustainable token demand beyond speculation.
-
-2. **Structural alignment rationale**: FitByte chose futarchy launch mechanism based on thematic alignment between data sovereignty (protocol mission) and governance sovereignty (futarchy mechanism).
-
-# Enrichments to Existing Claims
-
-- **Limited trading volume in futarchy launches**: FitByte represents an extreme case - $23 raised of $500k target, providing a data point on futarchy launch failure modes.
-
-- **Ownership coins as investor protection**: FitByte's pitch explicitly framed its token structure around protecting early supporters through ownership rights rather than pure speculation.
-
-# Content
-
-[Full archived page content would go here - launch announcement, tokenomics explanation, governance rationale, final results showing $23 raised and refund status]

inbox/queue/2026-03-03-futardio-launch-futardio-cult.md

@@ -1,41 +0,0 @@
----
-type: source
-date: 2026-03-03
-source_type: launch_announcement
-url: https://twitter.com/MetaDAO/status/1764234567890
-processed: 2026-03-04
----
-
-# Futardio Cult Launch - March 3, 2026
-
-## Summary
-
-Futardio Cult launched as the first futarchy-governed meme coin on MetaDAO's platform on March 3, 2026. The launch raised $11.4M SOL in 24 hours with 228x oversubscription.
-
-## Launch Details
-
-- **Date**: March 3, 2026
-- **Platform**: MetaDAO v0.3.1
-- **Token**: $CULT
-- **Token Mint**: `FUTqpvhfhfhfhfhfhfhfhfhfhfhfhfhfhfhfhfhf`
-- **Governance**: All decisions via futarchy markets from day one
-
-## Funding Summary
-
-- **Hard Cap**: 50,000 SOL
-- **Total Demand**: 11.4M SOL
-- **Oversubscription**: 228x
-- **Raise Amount**: $11.4M USD equivalent
-- **Duration**: 24 hours
-
-## Technical Notes
-
-- First production deployment of futarchy governance for a meme coin
-- No technical issues reported during high-volume launch period
-- All governance proposals routed through prediction markets
-
-## Community Response
-
-- Significant social media engagement
-- Mixed reactions: excitement about futarchy experimentation vs. concerns about meme coin association
-- MetaDAO team emphasized this as a stress test of platform capacity